Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 14, 2025 06:00 ET | Source: Zelluna ASA

Zelluna ASA: Invitation to Second Quarter 2025 results webcast presentation

Oslo, Norway, 14 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites you to a...
July 03, 2025 06:07 ET | Source: Zelluna ASA

Zelluna ASA - Grant of Share Options under Long-Term Incentive Program

Oslo, 3 July 2025: On the basis of the approval by the General Meeting on 29 April 2025 to authorize the Board of Directors of Zelluna ASA (the ‘Company’, OSE ticker “ZLNA”) to grant new shares to...
June 25, 2025 10:19 ET | Source: Zelluna ASA

Disclosure of share transfer from Inven2 AS

Issuer: Zelluna ASAISIN: NO0013524942Date of transaction: 25 June 2025 Inven2 AS, a major shareholder in Zelluna ASA, has transferred a total of 120,796 shares in Zelluna ASA to two inventors, in...
May 27, 2025 07:52 ET | Source: Zelluna ASA

Disclosure of Shareholding – Gjelsten Holding AS

Issuer: Zelluna ASAISIN: NO0013524942Date of event triggering the notification: 27 May 2025Threshold crossed: 5% In accordance with the Norwegian Securities Trading Act Section 4-3, Gjelsten Holding...
May 27, 2025 07:38 ET | Source: Zelluna ASA

ZLNA – New registered share capital

Oslo, 27 May 2025: Zelluna ASA (the "Company") refers to the announcement on 24 May 2025 regarding a resolution by the Company's Board of Directors to issue 227,096 new shares in the Company against...
May 24, 2025 02:38 ET | Source: Zelluna ASA

ZLNA – Issuance of shares through set-off of option exercise fee

Oslo, 24 May 2025: Zelluna ASA (the "Company") refers to the resolution by the Company's Annual General Meeting held on 29 April 2025 to grant the Company's Board of Directors an authorisation to...
May 08, 2025 01:00 ET | Source: Zelluna ASA

Zelluna ASA Reports First Quarter 2025 Financial Results and Provides General Business Update

Oslo, Norway, 8 May 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, announces its first...
April 30, 2025 02:00 ET | Source: Zelluna ASA

Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation

Oslo, Norway, 30 April 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites to a webcast...
April 29, 2025 08:50 ET | Source: Zelluna ASA

Zelluna ASA – Annual General Meeting held on April 29, 2025

Oslo, April 29, 2025: Zelluna ASA held its annual general meeting today April 29, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and available at the...
April 22, 2025 01:47 ET | Source: Zelluna ASA

Zelluna Reaches Major Milestone with Manufacturing Process Established in Preparation for Clinical Entry of ZI-MA4-1, its Novel TCR-NK Therapy Targeting Solid Tumours

Oslo, Norway, 22 April 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, has successfully...